TranScrip Internal Medicine

TranScrip expertise and experience extends to a wide range of Internal Medicine areas including nephrology, haematology, gastroenterology, rheumatology, immunology, endocrinology and cardiovascular diseases.

Additional therapeutic areas

Infectious Diseases, Oncology, RespiratoryCNS/Pain


TranScrip Internal Medicine Experts

TranScrip’s Internal Medicine team has worked on all phases of clinical development ranging from proof of concept / mechanism, submission of orphan designations including negotiations on the development plan, translational programmes to registrational work involving submissions and post-registration programs for big pharma and small biotech companies. TranScrip´s experience extends to a wide range of Internal Medicine areas including nephrology, haematology, neurology, gastroenterology, rheumatology, immunology, endocrinology and cardio-metabolic diseases. TranScrip has extensive experience working with regulatory authorities worldwide, including EMA, FDA and PMDA. TranScrip´s services range from ad-hoc advice to deployment of fully operational project teams.

Tim Joslin
Head of Internal Medicine

Tim leads TranScrip's clients' programmes in internal medicine product development, registration, and post-licensing. He has over 30 years of industry experience covering the complete product  life-cycle from "Target Product Profile" and national/global launches to post-patent strategies for cardiometabolic, immunology and other areas within the internal medicine therapeutic area.

Latest Internal Medicine News

03 June

Hyperlipidaemia and monoclonal antibodies – paying for outcome, by Senior Partner Gilbert Wagener for The British Journal of Cardiology

This article was originally published in the British Journal of Cardiology, Volume 21, Issue 3. To view the rest of this issue, and similar content, please visit

Forthcoming Events

There are currently no posts.

Company Product Phase Indication and Service
Top 50 Synthetic Analogue of Calcitriol Translational Hyperparathyroidism: Advisory Board support.
Top 50 EPO Glycoprotein Launch Anaemia: Participate as speaker and chairperson at the Nephrology Educational Winter Symposium.
Top 50 HIF-PH Inhibitor Translational Anaemia: Translational medicine, ad board and regulatory support (including for PIP) and support for various clinical research and clinical development documents.
Top 50 Lipoglycopeptide Translational Antibiotic and renal toxicity: Medical writing in renal impairment study.
Top 50 Phosphate Lowering Therapies CKD Launch Hyperphosphataemia: Chairing and support for symposium.
Medium Phosphate Binder Phase III Hyperphosphataemia: Medical Director and department responsbilities for clinical development, regulatory affairs, drug safety and commercial discussions for phase II through to phase III.
SME Various Translational Anaemia: Medical input to treatment and drug development of a product for iron deficiency anaemia in CKD.
Top 50 Phosphate Binder Phase III Hyperphosphataemia: Involvement in preparation of MAA and NDA submission clinical materials including CSRs, clinical summaries, defence of agency questions, support for scientific advice meetings.
Top 50 Iron Product Phase III Anaemia: Support for drug safety and clincal study reports for the submission.
Top 50 NA Mature Hyperphosphataemia: Advisory Board and symposia support.
Top 50 Thrombopoietin-Receptor Agonists Phase III Thrombocytopaenia: Review of clinical protocols, clinical development and writing of a PIP.